Satellos Biosciences (TSX:MSCL) reveals it has received approval to begin a Phase 1 clinical trial in Australia for SAT-3247.
Vous n'êtes pas connecté
DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors (GIST) pipeline landscape. It covers the pipeline drug profiles, including clinical and
Satellos Biosciences (TSX:MSCL) reveals it has received approval to begin a Phase 1 clinical trial in Australia for SAT-3247.
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner...
Wilson Sonsini Goodrich & Rosati advised MBX Biosciences on patent matters on the transaction. MBX Biosciences, Inc., a clinical-stage...
Highlights: India waives local clinical trials for breakthrough drugs from select developed countries Rule 101 t
Competitive: ICON Strategic Solutions: ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to...
Competitive: ICON Plc: ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance...
Negotiable: Proclinical Staffing: Proclinical is seeking a Director of Clinical Development to join a globally recognized pharmaceutical company....
Negotiable: Proclinical Staffing: Proclinical is seeking four Contract Clinical Study Specialists for a large pharmaceutical company based in London....
Competitive: Worldwide Clinical Trials - USA: Who we are Worldwide, a leading global contract research organization (CRO), works in partnership...
Competitive: ICON Plc: Job Advert Posting About the role ICON plc is a world-leading healthcare intelligence and clinical research organisation. From...